Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smoking Cessation Algorithm in HIV Primary Care
NCT03670316Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of varenicline, bupropion and nicotine patch in tobacco dependence (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: 7-day Point-prevalence Abstinence at 6 months. Started Aug 2020; status: completed.
02
Drugs
vareniclinebupropionnicotine patch
03
Conditions
tobacco dependence
Beyond the preview
Go deeper on NCT03670316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670316.